Ridogrel

This page contains recent news articles, when available, and an overview of Ridogrel but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Ridogrel (when available)

Pharmacology and use:
This drug is used with streptokinase as an adjunctive therapy to reduce the formation and size of blood clots. Blood clots can cause ischemic cardiac events (heart attacks). Ridorgel has the dual property of inhibiting the synthesis of thromboxane and blocking the receptors of thromboxane/prostaglandin/endoperoxides. It has been shown to accelerate the speed of recanalization and to delay or prevent reocclusion during systemic thrombolysis with tissue plasminogen activator (streptokinase). Used as an adjunctive therapy to induce thrombolysis in patients suffering acute myocardial infarction.

Mechanism Of Action:
Ridogrel inhibits thromboxane A2 synthase and also blocks the thromboxane A2/prostaglandin endoperoxide receptors. It is a more potent antiplatelet agent than aspirin and might offer an advantage over aspirin as an adjunct to thrombolysis in patients suffering from acute myocardial infarction.

News Articles on Ridogrel

Brand Names/Synonyms:
Ridogrel is also known by the following brand names and/or synonymsRIDOGREL; Ridogrel [Usan:Ban:Inn]; Ridogrelum [Inn-Latin]

Drug Category:
Ridogrel is categorized under the following by the FDA: Thrombolytic agents

Dosage Forms:
TABLETS

Absorption:
Rapidly absorbed after oral administration (30-60 min)

Interactions:
Not Available

Chemical IUPAC Name:
5-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]-methylidene]aminooxypentanoic acid

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.